[New possibilities in the hormonal therapy of metastatic carcinoma of the prostate].
The application of estrogens in cases of prostatic cancer was widely accepted due to the discovery that they decreased the serum testosterone level. Yet, it was soon evident that their application did not always lead to the expected therapeutic effect, and thus the scientists kept on searching for the substances which would overcome the drawbacks of estrogen therapy. The paper describes the mechanisms of the activity of the three new groups of drugs which could be taken as the alternative to the estrogen therapy or castration in cases of advanced prostatic cancer.
Cicin-Sain
D
D
Pasini
J
J
D000726:Androgen Antagonists / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D008297:Male; D011388:Prolactin / Q000037:antagonists & inhibitors*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone; D011388:Prolactin
Nove mogućnosti u hormonalnoj terapiji metastatskog karcinoma prostate.